Market Scenario:
Brest cancer is type of cancer developed in breast tissue. Formation of lump in a breast, red patches on the skin are the some of the common symptoms of the breast cancer. Obesity, lack of physical exercise, overexposure to radiation and drinking alcohol are some of the risk factor for developing breast cancer. According to WHO, it is the second most common type of cancer in women. Every year 200,000 new cases are diagnosed worldwide and this number is continuously increasing. Prevalence of breast cancer is more common in developed countries compare with developing countries. Increasing number of females suffering from breast cancer is the major factor for the growth of market. Beside this adoption of unhealthy lifestyle, increasing female geriatric population, exposure to harmful radiation and increasing governmental initiatives also contributed in the growth of the market. As no absolute treatment is available there is a scope for developing the market across the world. While on other hand high cost of the treatment, adverse effects associated with the therapy and long approval time for the drugs are responsible for restraining the growth of the market.
The global breast cancer market is expected to grow at a CAGR of 9.2% during forecasted period 2017-2023.
Segmentation
Global breast cancer market is segmented on the basis of type into invasive ductal carcinoma, invasive lobular carcinoma and other. On the basis of treatment they are segmented into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy and other. Chemotherapy is further segmented into antimetabolites, anthracyclines, taxanes and alkylating agents. Target therapy is further segmented into tyrosine kinase inhibitors and monoclonal antibodies Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors and others. On the basis of end users the market is segmented into hospital pharmacies, private pharmacies and other.
Regional Analysis
On regional basis, global breast cancer market is dominated by America. Changing lifestyle and increasing prevalence of breast cancer in America has driven the growth of the market. America breast cancer market is followed by Europe. Technological advances, increased life expectancy and healthcare expenditure of people is responsible for the growth of this market in America and Europe. Asia Pacific is expecting a fastest growth for the market.
Key Players for global wireless health and fitness devices market
Pfizer (US), Novartis AG (Switzerland), Oncogenex (US), Apthera Inc (UK), BioNumerik Pharmaceuticals (US), Oncothyreon Inc (US), Astellas (Japan), Bipar Sciences (US), Puma Biotechnology (US), Sanofi S.A. (US), Eli Lilly and Company (US), AstraZeneca (UK), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK), Genentech (US), Teva Pharmaceutical Industries (Israel), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare, Inc. (India), Gilead Sciences, Inc. (US), Bristol-Myers Squibb company (US), Actavis, Inc. (US), Hospira, Inc. (US), Bayer AG (Germany)